Cargando…
抗体偶联药物在肺癌中的研究进展与展望
Antibody drug conjugates (ADCs) are a novel class of anti-cancer drugs, which combined the specificity of monoclonal antibodies with the cytotoxic palyload via the linkers. Many ADCs have not only verified impressive activity in a variety of cancers, including breast cancer and hematological system...
| Formato: | Online Artículo Texto |
|---|---|
| Lenguaje: | English |
| Publicado: |
中国肺癌杂志编辑部
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9346152/ https://www.ncbi.nlm.nih.gov/pubmed/35899443 http://dx.doi.org/10.3779/j.issn.1009-3419.2022.102.22 |
| _version_ | 1784761582106968064 |
|---|---|
| collection | PubMed |
| description | Antibody drug conjugates (ADCs) are a novel class of anti-cancer drugs, which combined the specificity of monoclonal antibodies with the cytotoxic palyload via the linkers. Many ADCs have not only verified impressive activity in a variety of cancers, including breast cancer and hematological system tumors, but also in lung cancer. The aim of this study was to provide informations for practice by summarizing the mechanism of action, clinical application and problems and challenges of ADCs. |
| format | Online Article Text |
| id | pubmed-9346152 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | 中国肺癌杂志编辑部 |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-93461522022-08-17 抗体偶联药物在肺癌中的研究进展与展望 Zhongguo Fei Ai Za Zhi 肺癌创新药物研发 Antibody drug conjugates (ADCs) are a novel class of anti-cancer drugs, which combined the specificity of monoclonal antibodies with the cytotoxic palyload via the linkers. Many ADCs have not only verified impressive activity in a variety of cancers, including breast cancer and hematological system tumors, but also in lung cancer. The aim of this study was to provide informations for practice by summarizing the mechanism of action, clinical application and problems and challenges of ADCs. 中国肺癌杂志编辑部 2022-07-20 /pmc/articles/PMC9346152/ /pubmed/35899443 http://dx.doi.org/10.3779/j.issn.1009-3419.2022.102.22 Text en 版权所有©《中国肺癌杂志》编辑部2022 https://creativecommons.org/licenses/by/3.0/This is an open access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 3.0) License. See: https://creativecommons.org/licenses/by/3.0/. |
| spellingShingle | 肺癌创新药物研发 抗体偶联药物在肺癌中的研究进展与展望 |
| title | 抗体偶联药物在肺癌中的研究进展与展望 |
| title_full | 抗体偶联药物在肺癌中的研究进展与展望 |
| title_fullStr | 抗体偶联药物在肺癌中的研究进展与展望 |
| title_full_unstemmed | 抗体偶联药物在肺癌中的研究进展与展望 |
| title_short | 抗体偶联药物在肺癌中的研究进展与展望 |
| title_sort | 抗体偶联药物在肺癌中的研究进展与展望 |
| topic | 肺癌创新药物研发 |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9346152/ https://www.ncbi.nlm.nih.gov/pubmed/35899443 http://dx.doi.org/10.3779/j.issn.1009-3419.2022.102.22 |
| work_keys_str_mv | AT kàngtǐǒuliányàowùzàifèiáizhōngdeyánjiūjìnzhǎnyǔzhǎnwàng AT kàngtǐǒuliányàowùzàifèiáizhōngdeyánjiūjìnzhǎnyǔzhǎnwàng |